RxDoctor Payments DataLook up a doctor →

Song Yu, MD

Family Medicine · Birmingham, ALNPI 1912927625

Payments from drug & device makers

$1,690,857in general payments, 2019–2025

Across 510 payments — averaging $3315.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$1.1M
  • Abbott$221K
  • BD$114K
  • Orasure Technologies Inc.$99K
  • Merck$74K
  • Pfizer$71K
  • plus $50K from 37 others
$6,000in research payments, 2019–2025

Across 1 payment — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BD$6K

What the payments were for

  • Food & beverage$7,30699%
  • Education$160%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,690,857 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$341,352
Medicare patients
755
Services billed
31,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$343,520
FarxigaDapagliflozin Propanediol125$134,658
JardianceEmpagliflozin100$128,472
MounjaroTirzepatide62$86,485
EliquisApixaban78$66,321
KerendiaFinerenone40$37,532
TrulicityDulaglutide13$29,853
JanuviaSitagliptin Phosphate30$22,599
LinzessLinaclotide13$13,195
PaxlovidNirmatrelvir/Ritonavir192$8,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,779
Atorvastatin Calcium535$7,487
Doxycycline Monohydrate646$7,179
Levothyroxine Sodium457$6,633
Losartan Potassium353$5,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,576$343,520196 claims
AstraZenecaFarxiga$709$134,658125 claims
Boehringer IngelheimJardiance$125$128,472100 claims
Lilly USA, LLCMounjaro, Trulicity$679$116,33775 claims
PfizerEliquis, Paxlovid$71,464$74,897270 claims
BayerKerendia$534$37,53240 claims
MerckJanuvia$73,774$22,59930 claims
AbbVieLinzess$829$13,19513 claims
GSKTrelegy Ellipta$243$7,77912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →